Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study
John Hardman(Royal Marsden Hospital), Vinidh Paleri(Royal Marsden NHS Foundation Trust), Eric J. Moore(Mayo Clinic), J. Scott Magnuson(AdventHealth Orlando), Kathryn M. Van Abel(Mayo Clinic in Arizona), Jeroen Meulemans(KU Leuven), F. Christopher Holsinger(Stanford University), Peter Floros, Michael C. Topf(Vanderbilt University), Daniel J. Lin(Hainan Medical University), Alec Bonifer(Henry Ford Hospital), Heather M. Starmer(Palo Alto University), Niclas Rubek(Copenhagen University Hospital), Philippe Gorphe(Institut Gustave Roussy), Grégoire D’Andréa(Institut Gustave Roussy), Justin Roe(National Health Service), Umamaheswar Duvvuri(City University of New York), Evan Walgama(The University of Texas MD Anderson Cancer Center), Vincent Vander Poorten(KU Leuven), Avinash Beharry(University of Lausanne), Arun Balaji(Tata Memorial Hospital), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Grainne Brady(Royal Marsden Hospital), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Anand Subash(HCG Cancer Centre), Gouri Pantvaidya(Tata Memorial Hospital), Mikkel Hjordt Holm Larsen(Copenhagen University Hospital), David W. Hamilton(Newcastle upon Tyne Hospital), Scott A. Roof(Icahn School of Medicine at Mount Sinai), John R. de Almeida(Princess Margaret Cancer Centre), Brett A. Miles(Icahn School of Medicine at Mount Sinai), Tamer Ghanem(Henry Ford Hospital), S. Stephen(Newcastle upon Tyne Hospital), Laura Potts(King's College London), Emily Greenlay(Royal Marsden Hospital), Christian Simon(University of Lausanne), Surender Dabas, Chareeni Kurukulasuriya(Fred Hutch Cancer Center)
Cited by 32
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688